Telix Acquires Dedicaid
Summary
With the acquisition, Telix will accelerate the development of its AI platform denoted as Telix AI, by adding predictive capabilities alongside the imaging analysis module, being developed in partnership with Invicro LLC, which automates the classification of lesions to support standardisation in the imaging workflow. Following completion of the transaction, Telix aims to finalise validation activities and regulatory submissions (United States Food and Drug Administration (FDA) 510(k) and CE Mark (Europe)) for the AI platform as a ‘software as a medical device’ during 2023. Led by CEO Thomas Beyer, Dedicaid provides a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from available datasets, for use with positron emission tomography (PET) and other imaging modalities. Each CDSS application is trained to predict outcomes such as the severity of disease, risk to the patient and/or inform treatment decisions. It is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases.